Radforsk will distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research.

Our portfolio company OncoImmunity receives €2.2 million

OncoImmunity receives €2.2 million to roll out its machine-learning platform to enable the development of personalized cancer immunotherapies.

Nordic Nanovector receives Promising Innovative Medicine Designation

This acknowledges the potential of Betalutin® to offer therapeutic benefits to patients with follicular lymphoma, says CMO Lisa Rojkjaer in a press release.

Om Vaccibody i NRK EKKO

NRK EKKO med innslag om vår porteføljebedrift Vaccibody.

Targovax: Reports full data set on clinical trial of cancer vaccine TG01

Our portfolio company Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer: 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation […]

Vaccibody: First 10 patients enrolled and vaccination started

Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started.   Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release: “We are very pleased with the enrollment in the neoantigen trial and […]

Targovax: Encouraging interim results of ONCOS-102

Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma.   Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company: “Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete […]

Vaccibody in collaboration with prestige company Nektar Therapeutics

Our portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics.   The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist. In an interview with Norwegian financial paper “Finansavisen”, President and CSO  in Vaccibody, […]

New CEO in Photocure

Our portfolio company Photocure ASA has appointed Daniel Schneider as Chief Exceutive Officer and President.  Mr Schneider joins Photocure from the position of General Manager for Ablynx N.V. in North America. Mr Schneider will commence the position upon further agreement, expected prior to 1 November 2018. Erik Dahl will continue to serve as the acting […]